From Pulse 2.0 · Amit Chowdhry · · 30s
Arcturus Meiji Investment Details
Arcturus Therapeutics secures $50m Meiji investment at 80% premium for mRNA tech.
In brief
Arcturus Therapeutics secures $50m Meiji investment at 80% premium for mRNA tech. Arcturus Therapeutics received $50 million from Meiji Seika Pharma at 80% premium for its mRNA platform, accelerating cystic fibrosis and ornithine transcarbamylase deficiency treatments. Originally reported by Pulse 2.0.
Investment Terms
Meiji purchases Arcturus securities at $20.27 per share, an 80% premium, representing 7.9% of shares.
Technology License
Arcturus licenses ARCT-154 technology for an undisclosed therapeutic area.
Pandemic Partnership
Meiji and Arcturus agree to potential pandemic preparedness collaboration in Japan.
The key point
Arcturus Therapeutics received $50 million from Meiji Seika Pharma at 80% premium for its mRNA platform, accelerating cystic fibrosis and ornithine transcarbamylase deficiency treatments.
Read the TL;DR — this story on one card.

